Antimicrobial resistance (AMR) is clearly a serious global threat. To combat potential epidemic, requires both industry and government collaboration on an international level in antibiotics R&D investments, preventive measures and emergency response. As new resistance mechanisms rapidly spread throughout the developed and developing nations, this is putting our existing antibiotic pipeline under greater higher risk of failing to resolve many standard medical treatments, as well as compromising our achievements in modern standard medicine including cancer therapeutics and surgery.

Expanding horizons on the growing global threat of AMR for almost two decades, Superbugs & Superdrugs will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.

Working with an expert advisory board and an esteemed panel of industry leaders, the new agenda for the 18th annual show, will hone in on key topics such as R&D, collaboration, global epidemics, monoclonal anti-bodies, genome sequencing, rapid diagnostic tools, antibiotic alternatives, multi-resistance gram-negative infections, resistance prevention, antimicrobial peptides, combination therapies, microbiodata host interactions, plus much more!

Chairs for 2016:
Richard Bax, Senior Partner, Transcrip Partners
Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd

Elite International Speakers Include:
Line Matthiessen, MD PhD, Head of Unit Fighting Infectious Diseases and Advancing Public Health, European Commission
Melissa Stundick, Chief, Anti-Infectives Programme, BARDA
Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents
Prabhavathi Fernandes, President & CEO, Cempra Pharmaceuticals
Ankit Mahadevia, MD, President & CEO, Spero Therapeutics
Eszter Nagy, Co-founder, President and CSO, Arsanis
Jean de Gunzburg, Chief Scientific Officer, Da Volterra
David Cook, Chief Scientific Officer, Blueberry Therapeutics
Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience Ltd
Steven Boakes, Associate Director of Microbiology, Cantab Anti-Infectives

Key Business Benefits to Attend:

- Network with industry-leading experts on drug and antimicrobial material developments
- Learn new funding opportunities from BARDA and US National plans, to combat antimicrobial resistance
• Understand how the EU Commission’s practical approach in R&D can support your business growth
• Reinvigorate business models with Project DRIVE-AB and find workable solutions to strengthen drug development
• Build your antibiotic pipeline with new insights on microbiome profiling to fight multi-resistant gram negative infections
• Hear important discussions on tackling major bottlenecks that hinder development of new antimicrobial drugs with our star panel line-up

For further details and to register, visit the website at http://www.superbugssuperdrugs.com/inderscience or contact the team on +44 (0)20 7827 6000.